Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
Status:
Completed
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
The incidence of Hepatocellular Carcinoma (HCC) is currently increasing in Europe and in
France and about 2 / 3 of patients, are not eligible for curative treatment at the time of
diagnosis. The palliative management of patients with advanced and symptomatic disease is
complex and requires treatment combining anti-tumor activity and safety in patients with
impaired liver functions. Sorafenib is the standard of care in a palliative setting, but the
benefit of sorafenib in patient with altered liver function is uncertain. The aim of this
trial is to study the interest of sorafenib in patients with HCC and impaired liver function
compared to pravastatin (a drug with anti-tumoral activity in HCC) or to the combination
sorafenib/pravastatin or to best supportive care (usually used in these patients).
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Bordeaux
Collaborators:
Federation Francophone de Cancerologie Digestive UNICANCER